Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents

Ann Oncol. 2023 Jun;34(6):557-563. doi: 10.1016/j.annonc.2023.02.015. Epub 2023 Mar 21.

Authors

K Fizazi¹, S Gillessen²; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Affiliations

¹ Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
² Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.

PMID: 36958590
DOI: 10.1016/j.annonc.2023.02.015

No abstract available

Keywords: Clinical Practice Guideline; Lu-PSMA; abiraterone–prednisone; cabazitaxel; darolutamide; prostate cancer.

Publication types

Practice Guideline

MeSH terms

Humans
Male
Prostate-Specific Antigen
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Treatment Outcome

Substances

Prostate-Specific Antigen